ArticleCirculation reports2026
Inhaled Nitric Oxide Therapy and Changes in Pulmonary Artery Pulsatility Index During Venoarterial Extracorporeal Membrane Oxygenation Weaning in Cardiogenic Shock Requiring ECPELLA.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inhaled nitric oxide (iNO) selectively dilates pulmonary vessels and reduces pulmonary vascular resistance, potentially improving right ventricular (RV) function. However, its clinical benefit in patients with cardiogenic shock requiring ECPELLA (i.e., combined Impella® (ABIOMED) and venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains unclear. The aim of this study was to evaluate the impact of iNO on RV function in this critical population. Methods and Results: Between September 2017 and June 2023, we retrospectively analyzed 54 consecutive patients with cardiogenic shock treated with ECPELLA. Patients were divided into 2 groups based on the use of iNO. RV function was assessed using the pulmonary artery pulsatility index (PAPi) at the time of ECPELLA initiation (Pre-PAPi) and VA-ECMO weaning (Post-PAPi). The iNO group had a significantly lower Pre-PAPi, prompting propensity-score matching to adjust for baseline differences. After matching, the Post-PAPi was significantly higher in the iNO group than in the non-iNO group (1.95 [1.63-3.00] vs. 1.40 [0.50-2.05], P<0.05). A significant interaction between iNO use and PAPi change was observed (P=0.006), suggesting an iNO-mediated improvement in RV function. Conclusions: In patients with cardiogenic shock requiring ECPELLA support, adjunctive iNO therapy was associated with greater improvement in PAPi at the time of VA-ECMO weaning. These findings suggest a potential role for iNO in optimizing hemodynamics during the transition from ECPELLA to Impella-only support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.